Health News

Hispanic Heritage Month: Dr. Juan Pablo Frias, M.D. Discusses the Role of FibroScan for Clinical Research Programs

 
 
Dr. Juan Pablo Frias, M.D., Medical Director, National Research Institute joins eHealth Radio and the Health News and Technology Channels to discuss the role of FibroScan for clinical research programs, addressing racial disparities and improving patient management and outcomes.
Listen to interview with host Eric Michaels and guest Dr. Juan Pablo Frias discuss the following:
How has FibroScan impacted your clinical research programs at National Research Institute?
What role does FibroScan play for groups looking to get into this research? How does it factor into their participation?
As an endocrinologist looking to the future when the drugs for NASH become available, how do you see FibroScan best supporting clinical practice for managing patients on treatment?
What is the ethnic competition of your patient population? Is having access to FibroScan important for this population, or access to healthcare services in general?
Where do you see this going in terms of management and improving outcomes?
Dr. Frias, a native of Chile, completed his undergraduate studies at the University of Florida and received his medical degree from Vanderbilt University School of Medicine. After serving 5 years as a General Medical Officer in the US Navy, he completed his training in Internal Medicine at Vanderbilt University and the University of Tennessee, and his Fellowship in Endocrinology, Diabetes and Metabolism at the University of California, San Diego.
Dr. Frías has held leadership positions in Clinical and Medical Affairs at Eli Lilly, Amylin Pharmaceuticals, Pfizer, and Johnson and Johnson, where he served as Chief Medical Officer and Global Vice President of Clinical and Medical Affairs, Diabetes Care.
Dr. Frías has held academic positions at the University of Colorado Health Sciences Center, Barbara Davis Center for Diabetes, and the University of California San Diego School of Medicine, where he is currently on the clinical faculty. He is also active in the non-profit organization Taking Control of Your Diabetes (TCOYD), where he lectures at the organization’s Latino Initiative patient conferences and provides continuing medical education for healthcare providers. Dr. Frías has been involved in diabetes and metabolism-related research for over 15 years and has authored numerous publications in this field.
Website: https://echosens.com
Social Media Links: Facebook: facebook.com/fibroscan.echosens  Linkedin: linkedin.com/company/echosens  Youtube: youtube.com/user/EchosensTV Twitter: twitter.com/Echosens

What you Organically Need For Your Mind with Dr. Shara Ally

 
 
Dr. Shara Ally, Founder and CEO of NEUROorganics Inc., a revolutionary therapeutic counseling mental health service that fuses western and eastern approaches to care which has been recognized by Forbes, Yahoo Finance, Market Watch, and other major platforms again joins eHealth Radio and the Health News and Mental Health Channels.
Listen to interview with host Eric Michaels and guest Dr. Shara Ally discuss the following:
Can you tell us what NEUROorganics is and how this company came to be?
Who does NEUROorganics serve?
You have a service in NEUROorganics called NEUROmind. What does NEUROmind help a person solve?
What about NEUROsex? What does this service solve for someone?
Can you also describe how NEUROphysique and NEUROfinance services within NEUROorganics will help someone solve their problem?
What are some of the trends you are seeing right now given the post-traumatic stress people are experiencing from the pandemic, political shift, and the ongoing fight for equality?
Why should someone choose NEUROorganics over other mental health services?
Dr. Shara Ally is the Founder and Chief Executive Officer of the mental health company NEUROorganics Inc. Dr. Ally is the Head of the Student Wellness Department at Wilfred Laurier University, which focuses on the mental health and wellness of post-secondary students. She also sits on several boards including the Canadian Society of Allergy and Clinical Immunology, Global Research Federation Publishers, and the Mental health and Addictions Program Advisory Committee.
Through NEUROorganics, Dr. Ally provides mental health digital therapeutic counseling services for youth and adults managing stress in their personal and professional lives as it pertains to perceived challenges, intellectual and emotional development, and growth mindset. Since launching in September 2020, NEUROorganics has been recognized by Forbes, Yahoo Finance, Business Insider, Digital Health Buzz, and Market Watch. The company was born out of Dr. Ally's lived experiences, academic and professional opportunities.
Dr. Ally was awarded with a Fellowship in Chandigarh, India in 2019, where she met the Dalai Lama. After meeting and speaking with the Dalai Lama, she learned the eastern medicine benefits of approaching mental health and wellness through personal strengths and igniting personal resiliency and self-compassion for long-term mental health wellness. This working knowledge has been coupled with her expertise in psychiatry with a rich academic background in completing her Bachelor's of Science degree at McMaster University, Masters of Nursing and Business Administration, and her Doctorate degrees.
Shara has over a decade of professional experience of working in executive leadership roles in the mental health sector across hospital, community, and academic settings. She was also the President and Executive Officer of the Doctorate Nursing Practice Association at Western University in California, Adjunct Lecturer at the University of Toronto, and Research Assistant at Ryerson University in Toronto. Shara has had the opportunity to publish her research in the Family Physician Journal, Developmental Disabilities of Ontario textbook, and present across the USA, Canada, and Europe.
Overall, Dr. Ally's passion is concentrated in the mental health and wellness of people, and is an advocate for understanding the tools you already have to build resilience, inner strength, self-esteem and confidence.
 
 
Website: www.neuroorganics.com
Social Media Links: Facebook: facebook.com/NEUROorganics  Linkedin: linkedin.com/company/neuroorganics-inc Instagram: instagram.com/neuroorganics
The beliefs, views, ideas, thoughts and opinions expressed on any program are those of the persons appearing on the program and do not necessarily reflect the views and opinions of the eHealth Radio Network.

Going the Extra Mile: Central Ohio Primary Care Physicians Launches Vaccine "Delivery Service" to Provide Shots to Homebound Patients

 
 
Shawn Amer, Clinical Program Director at Central Ohio Primary Care with more than 70 practices serving over 400,000 patients and the largest independent primary care group in the country joins eHealth Radio and the Health Care and Health News Channels.
Listen to interview with host Eric Michaels and guest Shawn Amer discuss the following:
I understand that during the vaccine rollout, Central Ohio Primary Care launched a vaccine “delivery service” to vaccinate homebound patients. Can you tell us more about this initiative? Why did COPC launch this program?
What are some of the hurdles you have encountered in vaccinating home-bound seniors? What success have you seen through this program?
How has this program been meaningful to you and your team at Central Ohio Primary Care? Is there a patient experience that was particularly memorable?
I understand that COPC has launched other initiatives for senior patients during the pandemic to make healthcare more accessible. Can you tell us more about these efforts?
What are the benefits to Senior Access? Who is eligible for the program?
Shawn Amer joined Central Ohio Primary Care as Clinical Program Director in 2019. A graduate of Ohio State University, Shawn has held various directorial and management positions at healthcare organizations throughout the Midwest. During the COVID-19 pandemic, Shawn was a driving force in the creation of COPC’s vaccine “delivery service,” a new program that has been successful in vaccinating Columbus’ most vulnerable population: home-bound seniors.
 
 
Website: https://www.copcp.com
Social Media Links: Facebook: facebook.com/CentralOhioPrimaryCare Linkedin: linkedin.com/company/central-ohio-primary-care-physicians

New Charitable App Promotes “Active Aging”

 
 
Joe Liu, Founder of the Joe & Emmy Liu Charitable Foundation and developer of Lively Health, the first charitable self-directed lifestyle conditioning App for prevention of chronic conditions and active aging joins eHealth Radio and the Health News and Technology Channels.
Listen to interview with host Eric Michaels and guest Joe Liu discuss the following:
What was the impetus behind the creation of the Lively Health app?
What separates Lively Health from all the other “wellness” apps on the market?
You say your app promotes the concept of “active aging.” Can you explain exactly what that is and why it’s important?
It’s been proven that people in lower socioeconomic groups have less access to quality health care and are more susceptible to chronic medical conditions? Is that why you made the app free for download?
Your app takes a very holistic approach, asking the user to not only answer questions about their physical health but also their social, financial and psychological status. Do you feel that the medical establishment doesn’t place enough emphasis on these so-called “peripheral” areas when evaluating a person’s overall health?
Joe Liu is a Silicon Valley serial entrepreneur, who started the Joe & Emmy Liu Foundation with a vision to benefit humanity with his entrepreneurial and technical expertise. Liu started his first company Techlink Co. in 1984. He then co-founded Oplink Communications in 1995, led the IPO in 2000, and acquisition by Molex/Koch Industries in 2014. Liu angel invested in numerous high-tech companies, guided them to successful exits, and contributed tremendously to the growth of IT industry. Joe and his wife Emmy started The Joe and Emmy Liu Family Foundation in 2019, as a 501(c)3 private operating foundation using technology innovation to benefit human well-being.
 
 
Website: https://livelyhealth.org
Social Media Links: Facebook: facebook.com/Livelyhealthfoundation Linkedin: linkedin.com/company/livelyhealthfoundation Instagram: instagram.com/livelyhealthfoundation Twitter: twitter.com/livelyhealthapp

The Future of Keeping Your Hands & Home Clean Without Harmful Chemicals

 
 
David Weaver, the CEO of Aphex BioCleanse Systems, a sanitization solutions company focused on the development and distribution of non-toxic and water-based sanitization and disinfection products trademarked as Hy-IQ® Water joins eHealth Radio and the COVID-19 Information and Health News Channels.
Listen to interview with host Eric Michaels and guest David Weaver discuss the following:
How has cleaning and sanitization changed because of the COVID-19 pandemic?
Your company has created a cleaning substance called Hy-IQ Water. What is that and what does it do?
Why is Hy-IQ water better than alcohol-based hand sanitizers? Is it more effective?
What kind of studies have you done on Hy-IQ Water to make sure it works?
What would you say to someone who says that you need alcohol to kill germs?
SUMMARY: You don't need alcohol or chlorine to keep clean -- Hy-IQ Water is safer for humans AND the environment
Aphex BioCleanse Systems CEO David Weaver holds over 40 years of experience in engineering and design and is responsible for the creation of much of Aphex’s proprietary formulas. Previously, he spent over two decades as an optical engineer for Eastman Kodak, where he earned a name for himself by streamlining the company’s technology and operations, training its team around the world and innovating for the photography industry.
Following his role with Eastman Kodak, Weaver went on to found his own digital camera company, where he led the company to sell over $100 million within the first year through his innovations. He also helped Motorola launch the first-ever camera phone.
At Aphex, Weaver has spearheaded the creation of seven unique sanitization products that all use hydrogen-based cleaning technology to help keep people, places, pets, and products free of pathogens and our environment safe.
 
Website: https://aphexus.com
Social Media Links: Facebook: facebook.com/AphexBioCleanseSystemsTwitter: twitter.com/AphexSystems

July 28 is World Hepatitis Day: The Role of FibroScan to Cure HCV Among Veterans

 
 
Dustin Lee, Owner and President of Fidelis Sustainability Distribution, LLC, USMC scout sniper veteran and principal joins eHealth Radio and the Health News and Technology Channels to discuss the role FibroScan technology has played in curing hepatitis C virus (HCV) among the Department of Veterans Affairs (VA).
Listen to interview with host Eric Michaels and guest Dustin Lee discuss the following:
What are the challenges of treating liver disease among veterans?
What is the connection between hepatitis C virus (HCV) and nonalcoholic fatty liver disease (NAFLD)?
How did the VA eradicate HCV among veterans?
Why is FibroScan the VA’s liver assessment tool of choice, and how many VA Hospitals have purchased FibroScan?
What are the benefits of FibroScan for physicians treating veterans?
Fidelis, LLC is a certified Service-Disabled Veteran Owned Small Business as well as a U.S. Small Business Administration certified Small Disadvantaged Business (8(a)) company. Fidelis provides a wide variety of services for the Federal, State, and Local government nationwide as well as overseas.
Echosens, the developer of FibroScan®, is an innovative high-technology company offering a full range of products and services supporting physicians in their assessment and management of patients with chronic liver diseases. FibroScan is supported by over 2,500 peer-reviewed publications and examinations are covered by Medicare, Medicaid and many insurance plans.
Website: https://echosens.com
Social Media Links: Facebook: facebook.com/fibroscan.echosens  Linkedin: linkedin.com/company/echosens  Youtube: youtube.com/user/EchosensTV Twitter: twitter.com/Echosens

Douglas Dieterich, M.D., discusses role of FibroScan in the diagnoses of chronic liver disease

 
 
Douglas Dieterich, M.D., director of the Institute for Liver Medicine, Mount Sinai Health System, and professor of medicine for the Division of Liver Disease, Icahn School of Medicine at Mount Sinai joins eHealth Radio and the Health News and Technology Channels to discuss noninvasive liver screening to halt the progression of liver disease.
Listen to interview with host Eric Michaels and guest Dr. Douglas Dieterich discuss the following:
Please share with us the importance of ongoing assessment of liver stiffness and fat as part of a liver health assessment?
What role does FibroScan play in the diagnoses of chronic liver diseases and cirrhosis?
What is the risk of hepatocellular carcinoma (HCC) in people with long-term liver diseases, and if the liver is scarred by infection with hepatitis B or hepatitis C?
Tell us more about the use of FibroScan in hospital settings to improve outcomes and reduce costs in the assessment of liver disease.
Where do you see this going in terms of management and improving outcomes?
Dr. Douglas Dieterich is currently Professor of Medicine in the Division of Liver Diseases and also Director of Continuing Medical Education in the Department of Medicine at Mount Sinai School of Medicine, New York, NY.
He has a triple appointment in the divisions of Liver Disease, Gastroenterology, and Infectious Diseases.
Douglas T. Dieterich graduated from Yale University in New Haven, CT and received his Doctorate of Medicine from New York University of Medicine in NY. He completed his internship and residency in Internal Medicine at the Bellevue Hospital Center in New York, NY where he was also a fellow in the Division of Gastroenterology. He became Clinical Assistant Professor of medicine and then a Clinical Professor of Medicine, both at the New York University. He remains as an Adjunct Clinical Professor of Medicine at New York University School of Medicine.
Dr. Dieterich is an investigator for many ongoing clinical trials evaluating the safety and efficacy of new antiviral treatments for chronic hepatitis B & C.
Dr. Dieterich is a member of many professional societies and is a fellow of both the American College of Physicians and the American College of Gastroenterology. He has served on several committees of the AIDS Clinical Trials Group at the National Institutes of Health (NIH), including the Steering Committee of the Opportunistic Infections Core Committee and the Cytomegalovirus (CMV) Committee. He was Chair and Co-Chair, respectively, of the Enteric Parasites Committee and the Protozoan Committee. He also served on the NIH Study Sections for CMV and cryptosporidiosis.
Widely published, Dr. Dieterich is the author of numerous journal articles, abstracts and book chapters on viral hepatitis and AIDS associated infections of the gastrointestinal tract and liver.
Website: https://echosens.com
Social Media Links: Facebook: facebook.com/fibroscan.echosens  Linkedin: linkedin.com/company/echosens  Youtube: youtube.com/user/EchosensTV Twitter: twitter.com/Echosens

Plus Therapeutics: Gliblastoma, Rhenium NanoLiposome, and Harnessing the Power of Radiation Therapy

 
 
Dr. Marc Hedrick, President and CEO at Plus Therapeutics which is a clinical-stage pharmaceutical company focused on making a positive impact on patients’ lives and adding value to the healthcare system joins eHealth Radio and the Cancer Information and Health News Channels.
Listen to interview with host Eric Michaels and guest Dr. Marc Hedrick discuss the following:
What is Plus Therapeutics, and what is its mission?
Tell us about your background and what brought you to Plus Therapeutics?
What is Rhenium NanoLiposome (RNL™) and how is it delivered to cancerous brain tumors?
How could RNL help advance current treatment options for GBM and why is this important for patients?
Do you think most people understand radiation and its potential benefits as a cancer therapy?
What do you think is the most common misconception that people hold about radiation as a cancer treatment?
What’s next Plus Therapeutics? Is Plus developing other investigational candidates as part of its broader pipeline?
Dr. Marc Hedrick is the President and CEO at PLUS THERAPEUTICS, Inc. Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc. Dr. Hedrick is a trained general, vascular, and plastic surgeon and former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). Dr. Hedrick also served as Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA. Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and a MBA from The Anderson School at UCLA in 2005.
 
 
Website: plustherapeutics.com
Social Media Links: Facebook: facebook.com/plustherapeutics  Instagram: instagram.com/plustherapeutics  Twitter: twitter.com/plustxinc Linkedin: linkedin.com/company/plustherapeutics

Talking With One of America's Top Facial Cosmetic Surgeons!

 
 
Dr. Daria Hamrah, a top Double Board Certified Oral and Maxillofacial / Facial Cosmetic Surgeon in the US joins eHealth Radio and the Beauty and Health News & Plastic Surgery Information Channels.
Listen to interview with host Eric Michaels and guest Dr. Daria Hamrah discuss the following:
What procedures have people been getting most during the pandemic?
What new types of technology have you been using these days that is really changing the game?
With your charity foundation, tell us about it and why is providing services to kids in Colombia so important to you?
What tips can you give people when selecting a facial cosmetic surgeon?
What else do you have planned for 2021?
Dr. Daria Hamrah is a top double Board Certified oral and maxillofacial / facial cosmetic surgeon in America. When he isn't performing surgeries, Dr. Hamrah is also the co-founder of a non-profit called “The Alegria Foundation”, which helps children with cleft lip and palate and facial deformities; Dr. Hamrah travels to Colombia yearly and donates his time performing cleft lip procedures for the children there.
Website: https://novasurgicare.com
Social Media Links: Facebook: facebook.com/NOVASURGICARE Instagram: instagram.com/drhamrah Twitter: twitter.com/realdrhamrah YouTube: youtube.com/user/drhamrah

Echosens CEO Discusses How Company Helps Fight Liver Disease Epidemic

 
 
Jon Gingrich, the CEO of Echosens North America, a high-technology company offering the FibroScan family of products joins eHealth Radio and the Health News & Technology Channels.
Listen to interview with host Eric Michaels and guest Jon Gingrich discuss the following:
Please share with us the ongoing need for liver health assessment – and why the detection of fatty liver disease remains such a pressing challenge for Americans.

Please tell our audiences about the 2021 Echosens corporate initiatives and its focus on halting the progression of non-alcoholic fatty liver disease (NAFLD), fibrosis and cirrhosis. Describe new goals and objectives for building on the progress that Echosens has made in 2020.
Explain how Echosens plans to further expand the use of FibroScan technology in healthcare systems across America.

Can you describe specific programs and services to help educate specialists on the role of FibroScan?

How is Echosens helping payers and employers to understand the value of FibroScan?

Tell us about Echosens’ FAST score implementation and what successes you are seeing as a result of its use.

Explain how the COVID-19 pandemic has highlighted opportunities for Echosens to solve new problems, and support innovations that advance preventive care, address critical health care needs and improve outcomes for more Americans.
What is Echosens’ focus to continue bringing this awareness of NAFLD diagnosis and treatment in a post-pandemic world?
About Jon Gingrich, CEO, Echosens North America
With more than 20 years of global medical device and health care sales, marketing and general management experience at AxoGen, Inc., Hologic, Inc., Boston Scientific Corporation and Unilever, N.V, Gingrich now leads the development and execution of the Echosens U.S. strategy for expanding the utilization of FibroScan® technology in the assessment of chronic liver disease. As a member of the broader global executive leadership team, he works to implement the Company’s transformation plan and shape the future of Echosens.
About Echosens
Echosens, the developer of FibroScan®, is an innovative high-technology company offering a full range of products and services supporting physicians in their assessment and management of patients with chronic liver diseases. FibroScan is supported by over 2,500 peer-reviewed publications and examinations are covered by Medicare, Medicaid and many insurance plans.
Website: https://echosens.com
Social Media Links: Facebook: facebook.com/fibroscan.echosens  Linkedin: linkedin.com/company/echosens  Youtube: youtube.com/user/EchosensTV